IRWD Ironwood Pharmaceuticals, Inc.: תחזית צמיחת רווח נקי למניה לשנה הבאה

סמל ולוגו של המותג Ironwood Pharma (IRWD)

Ironwood Pharmaceuticals (IRWD) relies on physician recognition and the success of its primary IBS treatment. The consensus EPS forecast for the coming year confirms the stability of the company, whose metric stands at 7.60. Business efficiency is bolstered by cutting-edge developments in gut receptors and a streamlined drug delivery system that eliminates any supply disruptions.

Ironwood Pharmaceuticals Inc (IRWD): צמיחה צפויה ברווח נקי למניה בשנה הבאה מ-04.07.2022 עד 17.11.2026

פילוחים אנליטיים של חברת Ironwood Pharmaceuticals

ניתוח פונדמנטלי של החברה:IRWD, Ironwood Pharmaceuticals
פריט של המותג Ironwood Pharma

Ironwood Pharmaceuticals revenues depend on stable demand for the drug Linzess in the treatment of chronic gastrointestinal pathologies. This trend is reflected in experts' revisions of expected earnings per share, which captures the market valuation of the business model's efficiency. This indicator measures the consensus EPS growth forecast, allowing for the timely detection of expectation corrections following the publication of financial reports. By analyzing the estimated growth in net income per share for the coming year, an investor determines whether the asset is overvalued.